mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, Ä¡·á À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
mRNA Vaccines and Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type, Application, Treatment Type, End User, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1625460
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 129 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 2,538¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀåÀº ƯÈ÷ COVID-19 »çÅ·ΠÀÎÇØ ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¸Þ½ÅÀú RNA(mRNA) ±â¼úÀº COVID-19 ¹é½Å °³¹ßÀÇ »õ·Î¿î Á¢±Ù¹ýÀ¸·Î µîÀåÇÏ¿© Àü·Ê ¾ø´Â ¼Óµµ¿Í À¯¿¬¼ºÀ» Á¦°øÇß½À´Ï´Ù. ÀÌ Çõ½ÅÀº ÆÒµ¥¹Í »óȲ¿¡¼­ ½Å¼ÓÇÑ ¹é½Å »ý»êÀÇ ±æÀ» ¿­¾úÀ¸¸ç, µ¶°¨, ¾Ï, HIV µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ¹Ì·¡ ¹é½Å°ú Ä¡·áÁ¦¿¡ ´ëÇÑ ¹«ÇÑÇÑ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

±âÁ¸ÀÇ ¹é½Å °³¹ßÀº ÃÖÀûÀÇ Ç׿øÀ» ã¾Æ³»°í, ¹ÙÀÌ·¯½º »ùÇÃÀ» Áõ½Ä½Ã۰í, ´ë·®ÀÇ ¹é½ÅÀ» »ý»êÇϱâ À§ÇØ Á¾Á¾ ±ä °úÁ¤À» °ÅÃÄ¾ß Çß½À´Ï´Ù. ¹Ý¸é, mRNA ±â¼úÀº º´¿øÃ¼ÀÇ À¯Àü ¾ÏÈ£¸¦ ºü¸£°Ô ÇØµ¶Çϰí ÇÊ¿äÇÑ Ç׿øÀ» ¾ÏȣȭÇÏ´Â mRNA¸¦ ÇÕ¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. Áï, mRNA ¹é½ÅÀº À¯ÀüÀÚ ¼­¿­¸¸ ¾Ë¸é ¾î¶² °¨¿°¼º Áúȯ¿¡ ´ëÇØ¼­µµ Áï½Ã °³¹ßÀÌ °¡´ÉÇÏ´Ù´Â ¶æÀÔ´Ï´Ù. ÀÌ ´É·ÂÀ¸·Î ÀÎÇØ µ¶°¨À̳ª ÁöÄ« ¹ÙÀÌ·¯½º µî COVID-19 ÀÌ¿ÜÀÇ Áúº´¿¡ ´ëÇÑ mRNA ¹é½Å ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

mRNA Ä¡·áÁ¦´Â ´Ù¸¥ ¿ëµµ, ƯÈ÷ Á¾¾çÇп¡ ´ëÇÑ Àû¿ëÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, Moderna¿Í BioNTech¸¦ ºñ·ÔÇÑ ¿©·¯ ȸ»ç°¡ mRNA ±â¹Ý ¾Ï ¹é½Å¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇßÀ¸¸ç, Ãʱ⿡´Â À¯¸ÁÇÑ °á°ú¸¦ ¾ò¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ´Üµ¶À¸·Î ¶Ç´Â È­Çпä¹ýÀ̳ª ¸é¿ª¿ä¹ý°ú °°Àº ´Ù¸¥ Ä¡·á¹ý°ú ÇÔ²² ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.

mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¿ëµµº°·Î´Â mRNA ±â¼úÀÌ ¸ÂÃãÇü ¾Ï ¹é½Å ¹× ¾Ï ¸é¿ª Ä¡·á¹ý °³¹ßÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¾Ï ºÐ¾ß°¡ ¿¹Ãø ±â°£ µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Çüº°·Î´Â ±âÁ¸ ºñÁõÆøÇü mRNA ¹é½Å ºÎ¹®ÀÌ 2024³â mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²À» µ¶Â÷ÁöÇßÀ¸¸ç, ±× È¿´ÉÀÌ ÀÔÁõµÇ°í COVID-19 ¹ß»ý ½Ã ³Î¸® äÅõǾú±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.

¼¼°è ½ÃÀå¿¡¼­ ºÏ¹Ì´Â źźÇÑ ÇコÄɾî ÀÎÇÁ¶ó, R&D¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, mRNA ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ 2024³â ºÏ¹Ì°¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ±â¾÷Àº Pfizer Inc.; Moderna, Inc., BioNTech SE, GlaxoSmithKline, Daiichi Sankyo, BioNTech SE, CureVac N.V., AstraZeneca, Ethris, Sanofi, Arcturus Therapeutics, Innovac Therapeutics, Kernal Biologics, Pantherna Therapeutics, pHion Therapeutics, Recode Therapeutics, Rejuvenation Technologies, RNAimmune, Strand Therapeutics, Walvax, Ziphius Vaccines.ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå : À¯Çüº°

Á¦6Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå : Ä¡·á À¯Çüº°

Á¦8Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global mRNA vaccines and therapeutics market size is expected to reach USD 253.83 billion by 2034, according to a new study by Polaris Market Research. The report "mRNA Vaccines and Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (Self-Amplifying mRNA-Based Vaccines and Conventional Non-Amplifying mRNA-Based Vaccines), Application, Treatment Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The mRNA vaccines and therapeutics market has seen a rapid evolution, particularly with the emergence of the COVID-19 outbreak. Messenger RNA (mRNA) technology emerged as an approach for COVID-19 vaccine development, offering unprecedented speed and flexibility. This innovation has created the way for rapid vaccine production during the pandemic and holds immense potential for future vaccines and therapeutics for a wide array of diseases such as influenza, cancer, and HIV.

Traditional vaccine development often requires lengthy processes to identify the most suitable antigens, grow virus samples, and produce large quantities of vaccine doses. In contrast, mRNA technology allows for rapid sequencing of a pathogen's genetic code, followed by the synthesis of mRNA that encodes the required antigen. This means that mRNA vaccines can be developed for any infectious disease as soon as its genetic sequence is known. This capability has prompted the exploration of mRNA vaccines for diseases beyond COVID-19, including influenza and Zika virus.

mRNA therapeutics are being explored for other applications, particularly in oncology. Several companies, including Moderna and BioNTech, have begun clinical trials for mRNA-based cancer vaccines, with promising early results. These vaccines may potentially be used to treat a variety of cancers, as standalone therapies or in combination with other treatments such as chemotherapy and immunotherapy.

mRNA Vaccines and Therapeutics Market Report Highlights

In terms of application, the cancer segment is expected to grow at a rapid pace during the forecast period owing to the ability of mRNA technology to revolutionize cancer treatment by enabling the development of personalized cancer vaccines and cancer immunotherapies.

Based on type, the conventional non-amplifying mRNA-based vaccines segment dominated the mRNA vaccines and therapeutics market share in 2024 owing to their proven efficacy and widespread adoption during the COVID-19 outbreak.

In the global market, North America held the largest revenue share in 2024 due to robust healthcare infrastructure, significant investments in research and development, and rapid advancements in mRNA technology.

A few of the global key market players are Pfizer Inc.; Moderna, Inc.; BioNTech SE; GlaxoSmithKline; Daiichi Sankyo; BioNTech SE; CureVac N.V.; AstraZeneca; Ethris; Sanofi; Arcturus Therapeutics; Innovac Therapeutics; Kernal Biologics; Pantherna Therapeutics; pHion Therapeutics; Recode Therapeutics; Rejuvenation Technologies; RNAimmune; Strand Therapeutics; Walvax; and Ziphius Vaccines.

Polaris Market Research has segmented the mRNA vaccines and therapeutics market report on the basis of type, application, treatment type, end user, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

By Application Outlook (Revenue, USD Billion, 2020-2034)

By Treatment Type Outlook (Revenue, USD Billion, 2020-2034)

By End User Outlook (Revenue, USD Billion, 2020-2034)

By Regional Outlook (Revenue, USD Billion, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global mRNA Vaccines and Therapeutics Market Insights

5. Global mRNA Vaccines and Therapeutics Market, by Type

6. Global mRNA Vaccines and Therapeutics Market, by Application

7. Global mRNA Vaccines and Therapeutics Market, by Treatment Type

8. Global mRNA Vaccines and Therapeutics Market, by End User

9. Global mRNA Vaccines and Therapeutics Market, by Geography

10. Competitive Landscape

11. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â